Medroxyprogesterone acetate
- Generic Name
- Medroxyprogesterone acetate
- Brand Names
- Depo-provera, Depo-subq Provera, Premphase 28 Day, Prempro 0.625/2.5 28 Day, Provera
- Drug Type
- Small Molecule
- Chemical Formula
- C24H34O4
- CAS Number
- 71-58-9
- Unique Ingredient Identifier
- C2QI4IOI2G
- Background
Medroxyprogesterone acetate (MPA) is a progesterone derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy, manage pain in endometriosi...
- Indication
Medroxyprogesterone acetate (MPA) oral tablets are indicated to treat secondary amenorrhea, reduce the incidence of endometrial hyperplasia in postmenopausal women, and to treat abnormal uterine bleeding due to hormonal imbalance, not organic pathology. Oral tablets containing MPA and conjugated estrogens are indicated to prevent postmenopausal osteoporosis ...
- Associated Conditions
- Abnormal Uterine Bleeding, Amenorrhea, Endometrial Hyperplasia, Endometriosis related pain, Metastatic Renal Cell Carcinoma ( mRCC), Osteoporosis, Pain, Postmenopausal Osteoporosis, Pregnancy, Vasomotor Symptoms Associated With Menopause, Vulvo Vaginal Atrophy, Metastatic Endometrial carcinoma
- Associated Therapies
- Contraception, Estrogen Replacement Therapy, Hormonal Contraception therapy
The Effect of Post Ablation Medroxyprogesterone Acetate on Endometrial Amenorrhea Rates
- First Posted Date
- 2015-05-20
- Last Posted Date
- 2022-05-23
- Lead Sponsor
- Guy Waddell
- Target Recruit Count
- 60
- Registration Number
- NCT02449161
- Locations
- 🇨🇦
Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada
Endometrial Shedding Prior to Ovulation Induction Pilot Study
- First Posted Date
- 2015-01-16
- Last Posted Date
- 2015-11-13
- Target Recruit Count
- 50
- Registration Number
- NCT02340013
- Locations
- 🇨🇦
First Steps Fertility, Toronto, Ontario, Canada
🇨🇦Mount Sinai Hospital, Toronto, Ontario, Canada
Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-08-29
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- GOG Foundation
- Target Recruit Count
- 74
- Registration Number
- NCT02228681
- Locations
- 🇺🇸
Magee Women's Hospital of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Women's Cancer Center of Nevada, Las Vegas, Nevada, United States
Belatacept 3 Month Post Transplant Conversion Study
- Conditions
- Interventions
- First Posted Date
- 2014-08-11
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Lorenzo Gallon
- Target Recruit Count
- 28
- Registration Number
- NCT02213068
- Locations
- 🇺🇸
Northwestern University, The Comprehensive Transplant Center, Chicago, Illinois, United States
Efficacy of Cyclic DSG Compared With Cyclic MPA for the Treatment of Anovulatory DUB
- Conditions
- Interventions
- First Posted Date
- 2014-04-04
- Last Posted Date
- 2018-08-22
- Lead Sponsor
- Mahidol University
- Target Recruit Count
- 160
- Registration Number
- NCT02103764
- Locations
- 🇹ðŸ‡
Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
Quick Start of Highly Effective Contraception
- Conditions
- Interventions
- First Posted Date
- 2014-03-03
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 1030
- Registration Number
- NCT02076217
- Locations
- 🇺🇸
Planned Parenthood Association of Utah, West Valley City, Utah, United States
Study of a Progestin to Prevent Bleeding Associated With Initiation of Medical Menopause With GnRH Agonist
- Conditions
- Interventions
- First Posted Date
- 2013-01-28
- Last Posted Date
- 2015-03-17
- Lead Sponsor
- Kaiser Permanente
- Target Recruit Count
- 8
- Registration Number
- NCT01776203
- Locations
- 🇺🇸
Kaiser Permanente, Los Angeles, California, United States
Modulation of Mucosal and Systemic Immunity by Hormonal Contraceptives
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2014-01-07
- Lead Sponsor
- Thomas Cherpes, DVM, MD
- Target Recruit Count
- 7
- Registration Number
- NCT01750476
- Locations
- 🇺🇸
UPMC Adolescent Clinic of Oakland, Pittsburgh, Pennsylvania, United States
Postmenopausal Women,Treatment of Sleep Apnea and Co-morbidities
- First Posted Date
- 2011-11-16
- Last Posted Date
- 2013-03-11
- Lead Sponsor
- Turku University Hospital
- Target Recruit Count
- 34
- Registration Number
- NCT01472315
- Locations
- 🇫🇮
Sleep Research Unit, Department of Physiology, Turku University, Turku, Finland
DMPA & High Dose Oral Progestin (MPA) Tablets in Outpatient Treatment of Acute Excessive Vaginal Bleeding
- Conditions
- Interventions
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2014-03-13
- Lead Sponsor
- Women's Health Care Clinic, Torrance, California
- Target Recruit Count
- 48
- Registration Number
- NCT01148420
- Locations
- 🇺🇸
Harbor-UCLA Urgent Care, Torrance, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.